Pfizer Sues Oregon To Block Release Of Documents In Bextra/Celebrex Probe
Executive Summary
When Pfizer agreed to pay the states $60 million to end their investigation of Bextra and Celebrex marketing practices, the company thought it had eliminated that legal headache
You may also be interested in...
Pfizer Settlement Means New Oversight; Does It Mean A New Marketing Plan?
The government may be hoping the third time's the charm as it enters into a new corporate integrity agreement with Pfizer
Pfizer Settlement Means New Oversight; Does It Mean A New Marketing Plan?
The government may be hoping the third time's the charm as it enters into a new corporate integrity agreement with Pfizer
Bextra Settlement Coming Soon: Industry Should Brace For Impact
Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement